GNRH1 and diabetes mellitus: For example, treatment with GnRH agonists can lead to diabetes (due to the development of insulin resistance or altered insulin sensitivity), obesity, and other metabolic changes, including changes in lipid levels, which can exacerbate atherosclerotic diseases [44, 51–55].